scispace - formally typeset
F

Franck Lethimonnier

Researcher at French Alternative Energies and Atomic Energy Commission

Publications -  18
Citations -  1389

Franck Lethimonnier is an academic researcher from French Alternative Energies and Atomic Energy Commission. The author has contributed to research in topics: Diffusion MRI & In vivo. The author has an hindex of 12, co-authored 18 publications receiving 1242 citations. Previous affiliations of Franck Lethimonnier include IBM.

Papers
More filters
Journal ArticleDOI

Artifacts and pitfalls in diffusion MRI.

TL;DR: In this article, specific problems that one may encounter when using MRI scanner gradient hardware for diffusion MRI, especially in terms of eddy currents and sensitivity to motion are reviewed.
Journal ArticleDOI

Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis.

TL;DR: The model provides an invaluable basis for optimal design and delivery of nanoparticles to the brain and the maximum gap that may be safely generated between endothelial cells and the duration of opening of the BBB is studied.
Journal ArticleDOI

Optimized diffusion gradient orientation schemes for corrupted clinical DTI data sets.

TL;DR: With the proposed approach, sets of orientations responding to several corruption scenarios can be generated, which is potentially useful for imaging uncooperative patients or infants.
Journal ArticleDOI

A new paradigm for high-sensitivity 19F magnetic resonance imaging of perfluorooctylbromide.

TL;DR: The present work revisited the NMR properties of perfluorooctylbromide to derive a high‐sensitivity fluorine MRI strategy and shows that the harmful effects of J‐coupling can be eliminated by carefully choosing the bandwidth of the 180° pulses in a spin‐echo sequence.
Journal ArticleDOI

Magnetosomes, biogenic magnetic nanomaterials for brain molecular imaging with 17.2 T MRI scanner.

TL;DR: Preclinical studies of human pathologies in animal models will benefit from the combination of high magnetic field MRI with sensitive, low dose, easy‐to‐produce biocompatible contrast agents derived from bacterial magnetosomes.